BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thibault-Espitia A, Foucher Y, Danger R, Migone T, Pallier A, Castagnet S, G-Gueguen C, Devys A, C-Gautier A, Giral M. BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Am J Transplant. 2012;12:2754-2762. [PMID: 22883025 DOI: 10.1111/j.1600-6143.2012.04194.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Coelho V, Saitovitch D, Kalil J, Silva HM. Rethinking the multiple roles of B cells in organ transplantation. Current Opinion in Organ Transplantation 2013;18:13-21. [DOI: 10.1097/mot.0b013e32835c8043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
2 Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, Watson CJE, O'Sullivan AM, Chadwick JA, Foster KE, Jones RB, Devey LR, Richards A, Erwig LP, Savage CO, Smith KGC, Henderson RB, Clatworthy MR. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet 2018;391:2619-30. [PMID: 29910042 DOI: 10.1016/S0140-6736(18)30984-X] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 10.8] [Reference Citation Analysis]
3 van Gelder T, Baan C, Vincenti F, Mannon RB. Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma. Transpl Int 2013;26:938-48. [PMID: 23822608 DOI: 10.1111/tri.12140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Amore A. Antibody-mediated rejection. Curr Opin Organ Transplant. 2015;20:536-542. [PMID: 26348571 DOI: 10.1097/mot.0000000000000230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
5 Watanaboonyongcharoen P, Akkawat B, Tohthong T, Rojnuckarin P. High B-cell activating factor levels in multi-transfused thalassemia patients. Transfus Med 2021. [PMID: 34396626 DOI: 10.1111/tme.12806] [Reference Citation Analysis]
6 Lobashevsky AL, Higgins NG, Rosner KM, Mujtaba MA, Goggins WC, Taber TE. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation 2013;96:182-90. [PMID: 23778648 DOI: 10.1097/TP.0b013e3182962c84] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
7 Hoffman W, Lakkis FG, Chalasani G. B Cells, Antibodies, and More. Clin J Am Soc Nephrol 2016;11:137-54. [PMID: 26700440 DOI: 10.2215/CJN.09430915] [Cited by in Crossref: 158] [Cited by in F6Publishing: 85] [Article Influence: 22.6] [Reference Citation Analysis]
8 Banham GD, Clatworthy MR. B-cell biomarkers in transplantation - from genes to therapy: B-cell biomarkers in transplantation. Tissue Antigens 2015;85:82-92. [DOI: 10.1111/tan.12520] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
9 Leibler C, Matignon M, Pilon C, Montespan F, Bigot J, Lang P, Carosella ED, Cohen J, Rouas-Freiss N, Grimbert P, Menier C. Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells. Am J Transplant 2014;14:1173-82. [PMID: 24730563 DOI: 10.1111/ajt.12721] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
10 Li J, Luo Y, Wang X, Feng G. Regulatory B cells and advances in transplantation. J Leukoc Biol 2019;105:657-68. [PMID: 30548970 DOI: 10.1002/JLB.5RU0518-199R] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
11 Townamchai N, Eiam-Ong S. Biomarkers in kidney transplantation: From bench to bedside. World J Nephrol 2015; 4(5): 487-491 [PMID: 26558185 DOI: 10.5527/wjn.v4.i5.487] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Nouël A, Simon Q, Jamin C, Pers JO, Hillion S. Regulatory B cells: an exciting target for future therapeutics in transplantation. Front Immunol 2014;5:11. [PMID: 24478776 DOI: 10.3389/fimmu.2014.00011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
13 Shao J, Zhang J, Wu X, Mao Q, Chen P, Zhu F, Xu M, Kong W, Liang Z, Wang J. Comparing the Primary and Recall Immune Response Induced by a New EV71 Vaccine Using Systems Biology Approaches. PLoS One 2015;10:e0140515. [PMID: 26465882 DOI: 10.1371/journal.pone.0140515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
14 Alfaro R, Jaouad EKEB, Llorente S, Jimenez-Coll V, Martínez-Banaclocha H, Galián JA, Botella C, Moya-Quiles MR, Peña-Moral J, Minguela A, Legaz I, Muro M. Personalized Medicine for Kidney Transplantation: Association of Graft Survival and Acute Transplant Rejection with Genetic Variation in B Cell Activating Factor System Signaling. OMICS 2021;25:725-37. [PMID: 34714153 DOI: 10.1089/omi.2021.0099] [Reference Citation Analysis]
15 Geissler EK, Hutchinson JA. Immunological investigations empower transplant drug trials. The Lancet 2018;391:2578-9. [DOI: 10.1016/s0140-6736(18)31081-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
16 Wu S, Su X, Ye Q, Wei Y, Gao Y, Huang M, Chen Y, Wang J, Zhang Q, Fu Q, Li J, Wu C, Huang H, Xu B, Zhang H, Liu L, Wang C. Serum Soluble B Cell-Activating Factor Is a Non-Invasive Biomarker of Antibody-Mediated Rejection in Kidney Allograft With Satisfactory Risk Stratification Performance But Negligible Diagnostic Value. Front Immunol 2022;13:869444. [DOI: 10.3389/fimmu.2022.869444] [Reference Citation Analysis]
17 Liu M, Song W, Zhang J, Sun M, Sun X, Yu Q. Non-canonical NF-κB Plays a Pivotal Role in Non-Hodgkin’s Lymphoma. Cell Biochem Biophys 2015;72:681-5. [DOI: 10.1007/s12013-015-0518-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Xu H, He X, Xu R. B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome. J Immunol Res 2018;2018:5251801. [PMID: 29977928 DOI: 10.1155/2018/5251801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 Zhang H, Wang S, Su X, Fu Q, Li J, Wang J, Deng R, Wu C, Huang Q, Liu L, Wang C. The role of soluble B cell-activating factor in further stratifying the risk of antibody-mediated rejection post-renal transplant: A meta-analysis. Int Immunopharmacol 2020;79:106059. [PMID: 31865240 DOI: 10.1016/j.intimp.2019.106059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Lehnhardt AM, Strecker M, Eiermann T, Marget M, Thaiss F, Nashan B, Koch M. High B-cell activating factor is not associated with worse 3-year graft outcome in blood group-incompatible kidney transplantation with rituximab induction. Clin Transplant 2015;29:359-64. [PMID: 25627801 DOI: 10.1111/ctr.12523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
21 Sango C, Merino D, San Segundo D, Rodrigo E, Lopez-Hoyos M, Benito A, Ángeles Ramos M, Gómez-Román J, Arias M. B-Cell-Activating Factor Levels Are Associated With Antibody-Mediated Histological Damage in Kidney Transplantation. Transplant Proc 2016;48:2910-2. [PMID: 27932105 DOI: 10.1016/j.transproceed.2016.09.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
22 Comoli P, Quartuccio G, Cioni M, Parodi A, Nocera A, Basso S, Fontana I, Magnasco A, Sioli V, Guido I, Klersy C, Zecca M, Cardillo M, Ghiggeri GM, Ginevri F. Posttransplant Soluble B-Cell Activating Factor Kinetics in Pediatric Recipients of First Kidney Allograft. Transplantation 2015;99:243-9. [DOI: 10.1097/tp.0000000000000276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
23 Clatworthy MR. B-cell regulation and its application to transplantation. Transpl Int 2014;27:117-28. [PMID: 23909582 DOI: 10.1111/tri.12160] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
24 Parlakpinar H, Gunata M. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs. Immunopharmacol Immunotoxicol 2021;43:651-65. [PMID: 34415233 DOI: 10.1080/08923973.2021.1966033] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Salvadori M, Bertoni E. Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy. World J Transplant 2014; 4(1): 1-17 [PMID: 24669363 DOI: 10.5500/wjt.v4.i1.1] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
26 Irure-Ventura J, San Segundo D, Rodrigo E, Merino D, Belmar-Vega L, Ruiz San Millán JC, Valero R, Benito A, López-Hoyos M. High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection. Int J Mol Sci 2020;21:E779. [PMID: 31991734 DOI: 10.3390/ijms21030779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
27 Min JW, Kim KW, Kim BM, Doh KC, Choi MS, Choi BS, Park CW, Yang CW, Kim YS, Oh EJ, Chung BH. Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients. PLoS One 2016;11:e0162964. [PMID: 27631619 DOI: 10.1371/journal.pone.0162964] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
28 Xu H, Ma X, He X, Dong P, Xue D, Zhang Y, Zhang X. Serum miR-338-5p, soluble B-cell-activating factor, allo-antibodies, and renal transplantation. Transplant Proc 2015;47:337-42. [PMID: 25769569 DOI: 10.1016/j.transproceed.2014.11.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Karahan GE, Claas FH, Heidt S. B Cell Immunity in Solid Organ Transplantation. Front Immunol 2016;7:686. [PMID: 28119695 DOI: 10.3389/fimmu.2016.00686] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
30 Affandi JS, Montgomery J, Brunt SJ, Nolan D, Price P. The immunological footprint of CMV in HIV-1 patients stable on long-term ART. Immun Ageing 2015;12:14. [PMID: 26435726 DOI: 10.1186/s12979-015-0041-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
31 Reese SR, Wilson NA, Huang G, Redfield RR, Zhong W, Djamali A. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model. Transplantation 2015;99:1785-95. [DOI: 10.1097/tp.0000000000000736] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Mizrahi M, Cal P, Rosenthal M, Ochayon D, Shahaf G, Kaner Z, Kachker P, Lewis EC. Human α1-antitrypsin modifies B-lymphocyte responses during allograft transplantation. Immunology 2013;140:362-73. [PMID: 23829472 DOI: 10.1111/imm.12149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
33 Min JW, Shin YJ, Lee H, Kim BM, Park KH, Doh KC, Kim TM, Lim SW, Yang CW, Oh EJ, Chung BH. BAFF Inhibition Effectively Suppresses the Development of Anti-HLA.A2 Antibody in the Highly Sensitized Mouse Model. Int J Mol Sci 2021;22:E861. [PMID: 33467096 DOI: 10.3390/ijms22020861] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Gorbacheva V, Ayasoufi K, Fan R, Baldwin WM 3rd, Valujskikh A. B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells. Am J Transplant 2015;15:346-57. [PMID: 25496308 DOI: 10.1111/ajt.12984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
35 Xu H, Dong P, He X, Ma X, Xue D, Zhang Y, Zhang X. B-cell-activating factor code and human cytomegalovirus infection in renal transplant recipients: BAFF code and HCMV-TLR. Microbiol Immunol 2014;58:439-48. [DOI: 10.1111/1348-0421.12167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
36 Wang XZ, Wan Z, Xue WJ, Zheng J, Li Y, Ding CG. B-Cell Activating Factor Predicts Acute Rejection Risk in Kidney Transplant Recipients: A 6-Month Follow-Up Study. Front Immunol 2019;10:1046. [PMID: 31156628 DOI: 10.3389/fimmu.2019.01046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
37 Kościelska-Kasprzak K, Bartoszek D, Myszka M, Kamińska D, Boratyńska M, Krajewska M, Klinger M. B Cell Activating Factor (BAFF) in Long-term Kidney Transplant Recipients Is Not a Prognostic Marker for Allograft Dysfunction or Survival. Transplant Proc 2018;50:1750-4. [PMID: 30056894 DOI: 10.1016/j.transproceed.2018.03.121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Chhabra M, Conlon TM, Saeb-parsy K, Pettigrew GJ. BAFF and Associated TNF Superfamily Members in Renal Transplantation: An End to BLySful Ignorance. Transplantation 2013;96:853-9. [DOI: 10.1097/tp.0b013e3182997d34] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
39 Kühne L, Jung B, Poth H, Schuster A, Wurm S, Ruemmele P, Banas B, Bergler T. Renal allograft rejection, lymphocyte infiltration, and de novo donor-specific antibodies in a novel model of non-adherence to immunosuppressive therapy. BMC Immunol 2017;18:52. [PMID: 29258420 DOI: 10.1186/s12865-017-0236-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
40 Pankewycz O, Soliman K, Laftavi MR. The increasing clinical importance of alloantibodies in kidney transplantation. Immunological Investigations 2014;43:775-89. [DOI: 10.3109/08820139.2014.910016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
41 Vallin P, Désy O, Béland S, Wagner E, De Serres SA. Clinical relevance of circulating antibodies and B lymphocyte markers in allograft rejection. Clin Biochem 2016;49:385-93. [PMID: 26721422 DOI: 10.1016/j.clinbiochem.2015.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Weissenbacher A, Hautz T, Zelger B, Zelger BG, Mayr V, Brandacher G, Pratschke J, Schneeberger S. Antibody-mediated rejection in hand transplantation. Transpl Int 2014;27:e13-7. [PMID: 24266875 DOI: 10.1111/tri.12233] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
43 Schuster AM, Miesgang N, Steines L, Bach C, Banas B, Bergler T. B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation. Immunol Res 2021. [PMID: 34373996 DOI: 10.1007/s12026-021-09205-4] [Reference Citation Analysis]
44 Suchanek O, Clatworthy MR. Novel strategies to target the humoral alloimmune response. HLA 2020;96:667-80. [PMID: 33022883 DOI: 10.1111/tan.14092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Schuster A, Jung B, Hofbauer J, Kühne L, Zecher D, Banas B, Bergler T. B-cell activating factor BAFF reflects patients' immunological risk profile after kidney transplantation. Transpl Immunol 2017;45:35-41. [PMID: 28867309 DOI: 10.1016/j.trim.2017.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
46 Slavcev A, Brozova J, Slatinska J, Sekerkova Z, Honsova E, Skibova J, Striz I, Viklicky O. Soluble BAFF Cytokine Levels and Antibody-Mediated Rejection of the Kidney Allograft. Arch Immunol Ther Exp (Warsz) 2016;64:47-53. [PMID: 28083608 DOI: 10.1007/s00005-016-0428-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
47 Clatworthy MR. B cell modulation in transplantation. Clin Exp Immunol 2014;178 Suppl 1:61-3. [PMID: 25546764 DOI: 10.1111/cei.12513] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
48 Friebus-Kardash J, Wilde B, Keles D, Heinold A, Kribben A, Witzke O, Heinemann FM, Eisenberger U. Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival. Transpl Immunol 2018;47:10-7. [PMID: 29277566 DOI: 10.1016/j.trim.2017.12.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
49 Snanoudj R, Candon S, Roelen DL, Jais JP, Claas FH, Legendre C, Chatenoud L. Peripheral B-cell phenotype and BAFF levels are associated with HLA immunization in patients awaiting kidney transplantation. Transplantation. 2014;97:917-924. [PMID: 24827764 DOI: 10.1097/01.tp.0000438211.34842.5e] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
50 Chung BH, Kim KW, Yu JH, Kim BM, Choi BS, Park CW, Kim YS, Cho ML, Yang CW. Decrease of immature B cell and interleukin-10 during early-post-transplant period in renal transplant recipients under tacrolimus based immunosuppression. Transpl Immunol 2014;30:159-67. [PMID: 24709525 DOI: 10.1016/j.trim.2014.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
51 Bornacelly A, Mercado D, Acevedo N, Caraballo L. The strength of the antibody response to the nematode Ascaris lumbricoides inversely correlates with levels of B-Cell Activating Factor (BAFF). BMC Immunol 2014;15:22. [PMID: 24906685 DOI: 10.1186/1471-2172-15-22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
52 Ishida H, Inui M, Furusawa M, Tanabe K. Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation — Single-center study. Transplant Immunology 2013;28:93-9. [DOI: 10.1016/j.trim.2013.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
53 Chang Y, Shah T, Min DI. Association of genetic polymorphisms of macrophage inhibitory factor (MIF) and B-cell activating factor (BAFF) with the detection of donor specific antibodies in kidney allograft recipients. Hum Immunol 2017;78:621-8. [PMID: 28624489 DOI: 10.1016/j.humimm.2017.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Inaba A, Clatworthy MR. Novel immunotherapeutic strategies to target alloantibody-producing B and plasma cells in transplantation: . Current Opinion in Organ Transplantation 2016;21:419-26. [DOI: 10.1097/mot.0000000000000338] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
55 Afzali S, Salehi S, Shahi A, Esmaeili M, Farashi Bonab S, Peykari A, Bagherpour F, Ansaripour B, Soleimanian T, Pour-Reza-Gholi F, Amirzargar A. Investigating the Role of BAFF and Its Receptors in Renal Transplant Recipients with Chronic Antibody-Mediated Rejection. J Immunol Res 2021;2021:6654992. [PMID: 33748289 DOI: 10.1155/2021/6654992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Chen W, Ghobrial RM, Li XC. The Evolving Roles of Memory Immune Cells in Transplantation. Transplantation 2015;99:2029-37. [PMID: 26102615 DOI: 10.1097/TP.0000000000000802] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
57 Pongpirul W, Chancharoenthana W, Pongpirul K, Leelahavanichkul A, Kittikowit W, Jutivorakool K, Nonthasoot B, Avihingsanon Y, Eiam-Ong S, Praditpornsilpa K, Townamchai N. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients. Nephrology (Carlton) 2018;23:169-74. [PMID: 27888573 DOI: 10.1111/nep.12972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
58 Banham G, Prezzi D, Harford S, Taylor CJ, Hamer R, Higgins R, Bradley JA, Clatworthy MR. Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation. 2013;96:413-420. [PMID: 23842189 DOI: 10.1097/tp.0b013e318298dd65] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
59 Shin HS, Grgic I, Chandraker A. Novel Targets of Immunosuppression in Transplantation. Clin Lab Med 2019;39:157-69. [PMID: 30709504 DOI: 10.1016/j.cll.2018.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]